INTRODUCTION
Extracranial germ cell tumors (GCTs) are categorized as rare pediatric tumors. In children younger than 15 years, they account for approximately 3% of cancers. However, in adolescents (aged 15 to 19 years), this proportion increases to 14%. 1,2 The successful introduction of cisplatin-based chemotherapy in adults with GCT from the 1970s informed the design of subsequent pediatric protocols. [3] [4] [5] [6] 
EARLY CLINICAL TRIALS IN PEDIATRIC GCTS
GCTs are a heterogeneous group with respect to patient age, histologic features, and primary tumor location. Pediatric clinical trial design, which has traditionally incorporated all extracranial GCTs, not just a particular extracranial site such as testicular, has been challenged by this heterogeneity, in conjunction with the rarity of the tumor itself. In most countries, prospective pediatric clinical trials were limited to patients younger than 15 years. Each international pediatric GCT clinical trial organization has developed its own risk stratification and treatment protocols (usually featuring nonrandomized, single-arm studies) for patients they would categorize as low, intermediate, or high risk. In the United States, collaboration was recognized as essential early on in the history of pediatric clinical trials. In 1990, the Pediatric Oncology Group and Children's Cancer Group began one of the first intergroup (INT) collaborations to develop protocols for lowrisk (INT-0106) and high-risk (INT-0097) GCTs, on the basis of location and staging. For the purpose of this initial discussion, the postsurgical staging system used in these pediatric trials is described in Table  1 . The adult classifications are substantially more complex, and different stages may not be comparable. This is especially true with the staging of testicular GCTs, which will be discussed later. 7, 8 Age JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E VOLUME 33 ⅐ NUMBER 27 ⅐ SEPTEMBER 20 2015 eligibility varied, but these pediatric trials did include patients from the adolescent young adult (AYA) cohort, although the numbers were small ( Table 2) . For INT-0106, immature teratomas and stage I testicular malignant GCTs (Ͻ 10 years) were managed with observation only after initial surgery. Other tumors deemed low risk (INT-0106) that required chemotherapy, defined as stage II testicular (Ͻ 10 years) and stage I/II ovarian ( Ͻ 21 years) malignant GCTs, were treated with a modification of the successful adult bleomycin, etoposide, and cisplatin (BEP) regimen, with reduced-dose bleomycin because of concerns regarding fatal pulmonary fibrosis. 14, 16 Pediatric BEP (PEb) consisted of four cycles of standard adult doses of cisplatin (20 mg/m 2 per day administered for 5 days) and etoposide (100 mg/m 2 per day administered for 5 days), with bleomycin (15 mg/m 2 ) administered only on day 1 of each cycle, rather than once per week as in adult protocols. The overall 6-year survival rate for patients treated with PEb was 95.7%. 9 High-risk tumors, defined as stage III/IV ovarian, stage III/IV testicular, and stage I-IV extragonadal malignant GCT (all Ͻ 21 years) were treated in Intergroup Study INT-0097. High-dose cisplatin (200 mg/m 2 ) had shown promise both in a small randomly assigned trial from the National Cancer Institute in poor-prognosis GCTs 17 and in the treatment of progressive neuroblastoma. 18 Patients were randomly assigned between high-dose (HDPEb) and standard-dose (PEb) regimens. 10 Despite improved event-free survival (EFS), HDPEb did not improve overall survival (OS), most likely because of increased therapy-related toxicity. The study was not powered to detect differences in EFS or OS in separate strata. In addition, significant ototoxicity was noted with high-dose cisplatin, which was deemed unacceptable, especially given the young age of many patients with extragonadal disease. 10
RECENT PEDIATRIC GCT CLINICAL TRIALS
By the late 1990s, it became apparent that a wider Children's Cancer Group and Pediatric Oncology Group collaboration across the disease spectrum would benefit childhood cancer research by increasing sample size and decreasing administrative costs. After the merger of the four pediatric cooperative groups to form the Children's Oncology Group (COG), the COG GCT subcommittee redefined risk groups and developed the next generation of US GCT studies (Table 2) . For COG study AGCT0132, stage I ovarian GCTs were added to a low-risk group, and observation after surgical resection was advised, which had been proven effective for those with a testis primary tumor and on the basis of experience in ovarian primary tumors. 15, 19 Because the requirements for complete staging of an ovarian primary tumor are more complicated than for a testicular primary tumor, a rapid surgical review (within 72 hours of patient enrollment) was instituted to ensure that local physicians had complied with the protocol-mandated surgical guidelines. Among the 25 patients with ovarian stage I GCTs enrolled onto AGCT0132, the 4-year EFS and OS were 52% and 96%, respectively. 13 All but one patient, who had disease recurrence on observation, received salvage treatment with chemotherapy. The intermediate-risk groups for AGCT0132, defined as COG stage II to IV testicular, COG stage II/III ovarian, and COG stage I/II extragonadal GCT, were treated with three cycles of PEb (reduced from four cycles in a previous trial), and therapy was compressed from 5 to 3 days' duration per cycle, but maintaining overall dosing. The study has been closed, and data are being analyzed.
Patients who were high risk, defined as COG stage III/IV extragonadal disease, were enrolled onto sequential pilot studies of intensified therapy ( Table 2 ). The COG trial P9749 treated patients with HDPEb with the addition of the otoprotectant, amifostine, but unfortunately, rates of ototoxicity were not reduced. 11 In a second pilot AGCT01P1, escalating doses of cyclophosphamide did not improve on the response of standard PEb. 12 Patients with stage IV ovarian GCT were excluded from both of these trials.
CARBOPLATIN IN PEDIATRIC GCT TRIALS
The approach by pediatric oncologists in the United Kingdom has historically been different from the United States' approach. The first pediatric germ cell study used various chemotherapy regimens (Table  2) . Since 1989, because of toxicity concerns, the United Kingdom replaced cisplatin with carboplatin in its clinical regimens. Although carboplatin had already been shown to be definitively inferior to cisplatin in clinical trials in adults with testicular GCT, 20,21 the higher doses of carboplatin used in pediatric compared with adult trials produced promising results in children. 15 In the second GCT study, 15 The UK Children's Cancer and Leukemia Group (CCLG) third study is now closed and awaiting analysis. In this trial, all standard-risk patients received four cycles, and high-risk patients received six cycles, of JEb. In the third study, therapy was not extended for two more cycles after remission was documented, to avoid potential overtreatment.
INTERNATIONAL PEDIATRIC GCT COLLABORATION
Every national pediatric GCT group has struggled with few patients and the stratifications. 15, 19, 22, 23 The lack of consensus between different national groups on the relative importance of age, site, stage, and elevation in tumor marker levels resulted in variable treatment approaches. National nonrandomized trials for pediatric GCTs from the French, German, and Brazilian germ cell groups are shown in Table 3 . The major aspects of these trials were an attempt to modify therapy on the basis of response and, in German Maligne Keimaeltumoren studies, to use neoadjuvant chemotherapy before definitive surgery. [24] [25] [26] [27] Investigations also include the addition of ifosfamide and the deletion of bleomycin. Results were good, but there were no comparison groups and the number of patients was small. There was consensus, however, for the need for further clinical innovation, with three key questions to be addressed: Could late effects be reduced through either the elimination of chemotherapy in patients likely to be cured by surgery or the substitution of cisplatin with similarly effective, but less toxic, drugs? Could clinical outcomes be improved in those patients who were unlikely to be cured with standard therapy? And could biologic markers of prognostic significance be identified? A major limitation to this task was that without a common language, such as the International Germ Cell Consensus Classification (IGCCC), 28 developed for metastatic adult testicular GCT, designing trials across cooperative group boundaries would be impossible.
Consequently, investigators from the COG and CCLG established the Malignant Germ Cell International Collaborative (MaGIC) initiative and, in 2009, a memorandum of agreement was signed. Data from seven COG and CCLG pediatric GCT trials, which ran from 1985 to 2009 (Table 2) , were combined to form a data set of more than 1,000 patients. The primary goals of the collaboration were to establish risk factors for disease recurrence, incorporate these into a common risk stratification, and use this stratification as the basis for subsequent clinical trials.
By using the parametric cure model 29 to predict estimated longterm disease-free (LTDF) survival, multivariable analysis of the MaGIC data resulted in a revised risk stratification that was internally validated using the boot-strapping method (Table 4 ). 30 Poor outcome was associated with patients age 11 years or older, tumor site (ovarian or extragonadal v testicular), and stage IV disease. Poor risk was defined as less than 70% LTDF survival. In this data set, neither elevation of tumor marker serum ␣-fetoprotein (AFP) nor type of therapy (PEb v JEb) was predictive of outcome. The fundamental change in this risk-stratification system was the recognition that only children age 11 years or older were poor risk (expected LTDF survival, Ͻ 70%); younger children, even with advanced disease or extragonadal primary site, still had an excellent prognosis. The MaGIC database was an important first step toward development of treatment strategies on the basis of specified outcomes combining the importance of age, site, stage, and sex. However, although derived from the largest data set described in pediatric GCT, the parametric cure model warrants external validation in an independent cohort, which is currently being conducted using data from the Brazilian GCT-99 cohort. 27
COLLABORATION EXTENDED
The MaGIC pediatric data set is limited by relatively few adolescents (11 to 15 years) and even fewer adolescents older than 15 years and young adults. However, in a single-institution case series, adolescents with testicular GCT, controlling for IGCCC risk group, stage, and histologic features, had a lower 3-year EFS (59.9%) compared with children (87.2%) or adults (80.0%). This GCT study replicates the inferior outcomes for AYA in other malignancies. The cause of this survival gap is likely multifactorial: adolescent patients may experience fragmented care, under-representation in clinical trials, and, perhaps, a contribution from inherently more aggressive biologic factors. [31] [32] [33] Consequently, to further examine how the outcomes in adolescents compare with outcomes in adults, the MaGIC consortium has been expanded to include cohorts of AYA with GCT treated by other cooperative groups. Ovarian and testicular AYA data sets have been provided by the Gynecologic Oncology Group (GOG) and the UK Medical Research Council. The outcomes of adolescent versus young or older patients were analyzed with the goal of validating (and if necessary, amending) the MaGIC revised risk classification, 30 thus generating a final common language for future clinical trials.
One large obstacle to comparing outcomes of treatment for adolescents with GCT is the fact that each cooperative group has evolved its own staging system, which may or may not be comparable. Substantial differences exist between the COG pediatric staging system, the American Joint Committee on Cancer (AJCC) testicular staging system (Appendix Table A1 , online only), the IGCCC metastatic testicular system (Table 5) , and the International Federation of Gynecology and Obstetrics (FIGO) staging system used for ovarian GCT (Appendix Table A2 , online only). 7, 8 Staging of adult testicular GCT may be rationally divided into stage I and advanced/metastatic (outside the testis) disease. Stage I is consistent across age groups. Pediatric stages II to IV testicular GCT would be considered advanced/metastatic disease and be classified in various subcategories (stages II and III) in the AJCC system. The discussion of these differences between the pediatric and adult testicular classifications becomes important when comparing studies in adolescents. Data on adolescents with either staging system are limited. Unfortunately, pediatric data sets lack the important information necessary for AJCC staging. In clinical practice, IGCCC risk-based staging may be more important for determining actual treatment. The FIGO system has been developed for all ovarian cancers, most of which are epithelial (Appendix Table A2 ). The FIGO management of such tumors dictates substantially more abdominal and pelvic lymph node sampling than historically has been performed for ovarian GCT.
The FIGO system has both similarities and differences compared with pediatric GCT staging. One example is peritoneal leakage of tumor, which would be defined as stage III disease using pediatric staging, but only stage IC using FIGO; however, on the basis of age, both cohorts of patients would receive similar therapy. Pediatric stage I would be comparable to FIGO stage IA/IB, and patients in this group might be candidates for identical treatment. It is clear that adult staging systems contain more subdivisions than does COG pediatric staging. The staging systems may be comparable if all relevant clinicopathologic data required to make such assignments are made available. A prospective trial that collects all such data may be able to answer this question.
COLLABORATION AND FUTURE APPROACHES
Despite the constraints of different staging systems and risk assignment, US and UK pediatric groups are now exploring opportunities for collab-oration in future clinical trials with both adult and other pediatric study groups, building on the success of the MaGIC collaboration. In this setting, the next set of GCT clinical trials might be jointly sponsored by pediatric and adult clinical trial organizations. A trial for low-and intermediate-risk GCTs is currently under development. This trial will be cosponsored by COG and the newly formed US National Research Group, which includes GOG. Patients from birth to age 50 years will be eligible. According to the COG staging system (Table 1) , low-risk patients are defined as any stage I patient, including testicular, ovarian, and extragonadal sites. Recommended therapy will be active surveillance, which is an accepted strategy for pediatric and adult patients with testicular cancer 34,35 (Fig 1) . In adult patients with testicular GCT, issues that affect this decision include the following: the ability of different health services to provide a comprehensive surveillance program versus the potential increased rates of retroperitoneal lymph node dissection required after such surveillance; the long-term toxicity of adjuvant abbreviated BEP; and the balance between patient education and clinical guidance. 36,37 However, active surveillance will now be extended to all adult women with FIGO stage IA/B ovarian GCT (Appendix Table A2 ), after comprehensive staging according to GOG guidelines, and all patients with COG stage I extragonadal GCT (Table 1) , who would currently receive chemotherapy as standard care. 38 In reality, most patients with localized stage I extrago-nadalGCTsareyoungpediatricpatientswithsacrococcygealdisease;thus, this protocol will be a significant change in clinical practice for adult women with ovarian tumors and children with stage I extragonadal GCT. In addition, this trial will allow a critical reassessment of current COG and GOG ovarian staging guidelines. For intermediate-risk patients, the protocol will be a randomly assigned comparison of regimens containing carboplatin versus cisplatin (Fig 1) . Eligibility will include all patients, except those with stage I testicular and extragonadal disease, those with FIGO stage IA/IB ovarian tumors,andpatientsdefinedashavingapoorprognosis(patientsՆ11years with either stage IV ovarian or stage III/IV extragonadal GCT, and patients Ͼ 15 years with IGCCC intermediate-or poor-prognosis testicular GCT). In the MaGIC analysis, outcomes with carboplatin using PEb were not significantly different than outcomes with JEb, either overall or in any individual risk group. 39 This trial will test PEb versus JEb (area under the [concentration-time] curve of 7.9 mg/mL per minute) in children younger than 11 years and the adult regimen of BEP versus the regimen of carboplatin, etoposide, and bleomycin (administered once per week) in 
Absence of nonpulmonary visceral metastasis
Presence of nonpulmonary visceral metastasis (S0) or S1 STM S2 STM S3 STM HCG Ͻ 5,000 IU/mL HCG Ն 5,000 and Յ 50,000 IU/mL HCG Ͼ 50,000 IU/mL AFP Ͻ 1,000 ng/mL AFP Ն 1,000 and Յ 10,000 ng/mL AFP Ͼ 10,000 ng/mL LDH Ͻ 1.5ϫ ULN LDH Ն 1.5 ϫ ULN and Յ 10 ϫ ULN LDH Ͼ 10 ϫ ULN NOTE. Adapted from the International Germ Cell Cancer Collaborative Group. 28 The International Germ Cell Consensus Classification is a prognostic factor-based staging system for metastatic germ cell cancers. Abbreviations: AFP, ␣-fetoprotein; HCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; RP, retroperitoneal; S0, normal marker; STM, serum tumor marker; S1, S2, S3, range listed above; ULN, upper limit of normal.
‫ء‬
Nonpulmonary visceral metastasis refers to metastasis involving organs other than lung (lymph nodes do not count). AYA patients age 11 to 25 years (Fig 1) . The number of courses of chemotherapy delivered within and between each arm will be determined by analyses of the completed COG AGCT0132 study, which are in progress.
Because outcomes in children with GCT younger than 11 years are excellent, the pediatric collaboration on this trial will be extended beyond COG and CCLG, to have sufficient power to investigate whether carboplatin is comparable to cisplatin in terms of EFS. Three large pediatric clinical centers will therefore be included: Boldrini Children's Cancer Hospital (Campinas, Brazil), TATA Memorial Hospital (Mumbai, India), and Children's Cancer Hospital (Cairo, Eygpt). These three centers have appropriate approvals for participation in international pediatric clinical trials.
POOR-PROGNOSIS GCT
Through the application of the IGCCC staging system, 28 men with metastatic GCT can be assigned to good-, intermediate-, and poorprognosis categories (Table 5 ). 28 The term stage IV testicular GCT has therefore been eliminated from most adult testis cancer studies. In the pediatric studies, patients with gross disease and retroperitoneal lymphadenopathy were considered as having stage III disease, and only those with distant metastatic sites were defined as having stage IV disease. In the MaGIC analysis, postpubertal males (Ն 11 years) with COG stage IV testicular GCT had LTDF survival of 83%. Even when the IGCCC risk classification was applied to all such adolescent males with metastatic testicular GCT, a group with less than 80% LTDF survival could not be identified. This may be because most patients in the MaGIC data set were younger than 15 years, with only 22 patients in the 15-to 19-year age group. In contrast, patients 11 years or older with COG stage IV ovarian GCT and COG stage III/IV extragonadal GCT had poor rates of LTDF survival in the MaGIC analysis (67%; 65% and 40%, respectively). Although the MaGIC data set is the largest GCT data set available, it lacks sufficient information to apply the IGCCC classification to every patient. 22, 30 In addition, adolescents (age 15 to 19 years) may do less well than those slightly older or younger, when adjusted for stage and IGCCC risk group, 40 and are not well represented in clinical trials. Until further data are available, treatment assignment according to IGCCC prognostic categories seems prudent for postpubertal adolescent boys with metastatic GCT.
Answering clinically important questions in randomized clinical trials (RCTs) for poor-prognosis patients with GCT will be impossible without the inclusion of young adult patients and, in particular, patients with testicular GCT, given the 10-fold higher incidence of testicular GCT compared with ovarian GCT; therefore, collaboration with the testicular GCT community is essential for the development of RCTs in poor-risk disease. BEP has been the standard of care for adult testicular GCT for the past three decades. 4 Patients classified as having good-prognosis metastatic GCT, according to IGCCC, achieve a durable remission (90%) with three cycles of BEP. 41,42 Several strategies have been tested in phase II and III clinical trials for patients with poor-prognosis IGCCC disease, including the use of alternative or additional chemotherapy agents, 43-45 more complex multidrug regimens, [46] [47] [48] and high-dose chemotherapy and stem cell support. 36, 45, 49, 50 Unfortunately, none of these strategies has demonstrated clear improvement in cure rates.
An approach currently being investigated for poor-prognosis patients is dose intensification, a strategy that can increase the sensitivity of tumors to chemotherapy by increasing dose per unit of time. This can be attained by increasing the amount of drug per cycle (high-dose chemotherapy, unsuccessful as already noted above) or, alternatively, shortening the time between cycles (accelerated or dosedense treatment). 51 For example, accelerated timing has been used successfully in Ewing sarcoma 52 etoposide, administered every 2 weeks (instead of every 3 weeks), with bleomycin administered once per week and growth factor support. Although the cycles with cisplatin and etoposide were compressed, patients still received all 12 bleomycin doses, administered once per week. The phase I/II data showed acceptable toxicity and promising efficacy. 53 Another approach for patients with poor-risk GCT is whether those patientswhoarelikelytoexperiencefailureofstandardBEPtreatmentcan be identified early during BEP treatment and switched to more intensive therapy in real time. Retrospective reports have suggested that men with GCT and inadequate tumor marker decline (AFP) after initiation of chemotherapy are a poor-prognostic group. 50,54 A recent randomized trial, GETUG 13, 55 intensified therapy among patients with a poor AFP marker response to one cycle of BEP. There was a 10% increase in EFS compared with those who continued to receive standard-dose BEP; however, OS was similar between the two groups. The complexity of the GETUG 13 regimen, as well as the inclusion of insufficiently active or more toxic therapy, makes widespread adoption of this strategy unlikely. However, continued investigations of potential response-based strategies should be pursued.
Collaborators in pediatric oncology, medical oncology, and gyneco-logiconcologyhavediscussedproposalsforpatientsage11yearsandolder with poor-risk disease. The premise was that an RCT with increased samplesize,includingmaleandfemaleAYAwiththesamepredictedpoor outcome, was feasible. Perhaps, planning of a tentative joint RCT, simultaneously evaluating two or, perhaps, three of the most promising strategies (Fig 1) , was possible. Several promising regimens, such as Accel-BEP, 53 carboplatin, bleomycin, vincristine, and cisplatin with BEP (CBOP-BEP), 48 and first-line paclitaxel, ifosfamide, and cisplatin (TIP), 56 are being discussed. In the interim, pediatric groups continue to explore opportunities for collaboration with adult cooperative trial groups to establish feasibility of this strategy as a means to increase accrual and expedite evaluation of new approaches, especially in AYA. One option might be joining a currently open poor-prognosis adult GCT trial. One regimen under consideration for a multiarm trial is the currently active study, ANZUP 1302 (Australia and New Zealand), a phase III RCT of standard BEP versus accelerated BEP treatment for patients with IGCCC intermediate-and poor-prognosis GCT. This approach might provide the opportunity to demonstrate that a pediatric clinical trial group and a testicular cancer trial group can collaborate successfully across international boundaries.
Fortunately, for patients with relapsed GCT, salvage therapy is often successful. Salvage therapies have included other conventional chemotherapy agents, such as the TIP regimen and high-dose chemotherapy with or without stem-cell rescue. 50,57-61 However, the lack of RCTs in patients with relapsed GCT has not allowed for identification of the optimal salvage therapy. An international collaborative RCT, the Randomized Phase III Trial of Initial Salvage Chemotherapy for Patients with Germ Cell Tumors (TIGER) study (Alliance 0311102/EORTC 1407), will compare OS in patients with relapsed GCT treated with TIP or paclitaxel and ifosfamide, followed by high-dose carboplatin/etoposide. More important, because of the previous engagement of the pediatric and adult testicular communities through MaGIC, COG has been invited to cosponsor the Alliance trial, and the concept has been approved by the COG Science Council. The TIGER trial is expected to open in 2015.
BIOLOGICALLY-BASED TREATMENT
Advancement of biologic understanding of GCT, both pediatric and adult, is essential. Definitive pediatric GCT biologic studies have historically been hampered by the lack of available specimens, a hurdle that has been overcome by the MaGIC collaboration. Key differences in genomic changes have been identified in mediastinal tumors in children younger than 8 years and in those 8 years or older. 62 The patterns of gains and losses were similar to age-matched GCTs at other sites. In studies of adults with GCT, a prognostic mRNA gene expression signature was identified and validated with relatively few patients with poor clinical outcome. 63 However, Palmer et al 64 showed that GCTs in children have a protein-coding gene expression profile distinct from GCTs occurring in adults; therefore, whether the adult prognostic mRNA signature applies to children and adolescents remains to be determined. Other biologic parameters (eg, microRNAs) seem to be universally clinically informative in GCTs. 65, 66 It is hoped that collaboration will enhance not only understanding of basic GCT biologic features in children, adolescents, and young adults, but may enhance diagnosis, disease monitoring, risk stratification, and the identification of targetable mutations across the diverse clinical spectrum of extracranial GCT disease.
CONCLUSION
For too long, the study of GCT has been hampered by arbitrary clinical divides on the basis of age and sex. We can enhance the study of GCT through the generation of large clinical trial data sets that encompass all age groups and multiple cooperative groups with different treatment strategies. The planning of joint future trials is moving forward because of the persistent efforts of many groups. These studies will include an international attempt to prospectively collect biologic specimens that may ultimately improve diagnosis, disease monitoring, and risk stratification, and identify potential targets for treatment. Well-designed RCTs should allow improvement of clinical outcomes with reduced toxicity. One more facet about the study of rare pediatric cancers should be noted: Funding limitations have particularly hampered the study of GCT. The MaGIC studies and present collaborations could not have occurred without strong support and funding from COG and CCLG, as well as the Teenage Cancer Trust (United Kingdom) and other charities, such as the Katie Walker Fund (United Kingdom), Bridging the GAP (United States), The Franklin Foundation (Unites States), and the Dana Farber/Boston Children's Cancer and Blood Disorders Center. Investigators and patients are indebted to these valiant people.
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No evidence of primary tumor (eg, histological scar in testis) pN0
No regional lymph node metastasis pTis Intratubular germ cell neoplasia (carcinoma in situ) pN1 Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to five nodes positive, none Ͼ 2 cm in greatest dimension pT1
Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis pN2 Metastasis with a lymph node mass Ͼ 2 cm but not Ͼ 5 cm in greatest dimension; or more than five nodes positive, none Ͼ 5 cm; or evidence of extranodal extension of tumor pT2
Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis pN3 Metastasis with a lymph node mass Ͼ 5 cm in greatest dimension pT3 Tumor invades the spermatic cord with or without vascular/lymphatic invasion pT4
Tumor invades the scrotum with or without vascular/lymphatic invasion Marker study levels within normal limits S1 LDH Ͻ 1.5 ϫ N ‫ء‬ and hCG (mlu/mL) Ͻ 5,000 and AFP (ng/mL) Ͻ 1000 S2 LDH 1.5-10 ϫ N or hCG (mlu/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000 S3 LDH Ͼ 10 ϫ N or hCG (mlu/mL) Ͼ 50,000 or AFP (ng/mL) Ͼ 10,000 NOTE. Used with the permission of the American Joint Committee on Cancer (AJCC; Chicago, IL). The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010), published by Springer-ScienceϩBusiness Media, LLC (SBM). (For complete information and data supporting the staging tables, visit http://www.springer.com). Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC. All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. Abbreviations: AFP, ␣-fetoprotein; hCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; NCCN, National Comprehensive Cancer Network. ‫ء‬ N indicates the upper limit of normal for the LDH assay. Positive RP LN only (IIIA1i Ͻ 10 mm) (IIIA1ii Ͼ 10 mm) IIIA2
Microscopic, extrapelvic (higher than pelvic brim), peritoneal involvement with or without 
